🔎 Trials Near Me

Beranda › Liposarcoma › New Jersey

Uji klinis Liposarcoma di New Jersey

5 studi untuk Liposarcoma mencari peserta di lokasi di New Jersey.

Kota di New Jersey

Teks studi resmi (Bahasa Inggris)

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Bergen, Montvale
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06422806

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06843967

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  • Cooper Hospital University Medical Center, Camden
  • HMH-Hackensack University Medical Center, Hackensack
  • Jersey Shore University Medical Center, Neptune City
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04031677

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Hackensack University Medical Center, Hackensack
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07089992

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.